News
  Date Title View
Oct 27, 2016
- Study Successfully Achieves Primary Efficacy Endpoint - - Company Separately Announces Withdrawal of RhopressaTM NDA, with the Expectation of Refiling in January 2017 - Conference Call and Webcast Today, October 27, at 5:00 p.m. ET IRVINE, Calif.--(BUSINESS ...
Oct 25, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the "Company"), announced today that its third quarter 2016 financial results will be released after the market closes on Wednesday, November 2, 2016. Following the release, the Company will host a live conference call and webcast at ...
Sep 28, 2016
Webcast to Begin at 12:00p.m. Eastern Time IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast of its Investor Day taking place on Wednesday, October 5, 2016 at 12:00p.m. ET in New York, NY. ...
Sep 16, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the pricing of a regist...
Sep 15, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a...
Sep 14, 2016
RoclatanTM Successfully Achieves Primary Efficacy Endpoint in Mercury 1 Study Conference Call and Webcast Today, September 14, at 5:00 p.m. ET IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused...
Sep 6, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the submission of its N...
Aug 4, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of t...
Aug 3, 2016
NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02% On Schedule for Filing This Quarter Mercury 1 Phase 3 Topline Readout for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Expected in September 2016 Conference Call and Webcast Today, August 3,...
Jul 27, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the "Company"), announced today that its second quarter 2016 financial results will be released after the market closes on Wednesday, August 3, 2016. Following the release, the Company will host a live conference call and webcast at ...
Page: FirstPrevious
3
NextLast
= add release to Briefcase